BIO-RAD LABORATORIES -CL B (BIO.B) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:BIO.B - US0905721082 - Common Stock
310.7 USD
-3.7 (-1.18%)
BIO.B gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. BIO.B has an excellent financial health rating, but there are some minor concerns on its profitability. BIO.B is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BIO.B had positive earnings in the past year.
BIO.B had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BIO.B reported negative net income in multiple years.
Each year in the past 5 years BIO.B had a positive operating cash flow.
1.2 Ratios
BIO.B has a Return On Assets (-6.97%) which is in line with its industry peers.
BIO.B has a Return On Equity (-10.03%) which is comparable to the rest of the industry.
BIO.B's Return On Invested Capital of 2.26% is fine compared to the rest of the industry. BIO.B outperforms 62.07% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BIO.B is significantly below the industry average of 13.53%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
With a decent Operating Margin value of 10.27%, BIO.B is doing good in the industry, outperforming 70.69% of the companies in the same industry.
BIO.B's Operating Margin has been stable in the last couple of years.
BIO.B has a Gross Margin of 52.42%. This is in the better half of the industry: BIO.B outperforms 62.07% of its industry peers.
In the last couple of years the Gross Margin of BIO.B has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIO.B is destroying value.
Compared to 1 year ago, BIO.B has less shares outstanding
Compared to 5 years ago, BIO.B has less shares outstanding
The debt/assets ratio for BIO.B is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.42 indicates that BIO.B is not in any danger for bankruptcy at the moment.
BIO.B's Altman-Z score of 3.42 is fine compared to the rest of the industry. BIO.B outperforms 65.52% of its industry peers.
BIO.B has a debt to FCF ratio of 3.57. This is a good value and a sign of high solvency as BIO.B would need 3.57 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.57, BIO.B is in the better half of the industry, outperforming 77.59% of the companies in the same industry.
BIO.B has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
BIO.B has a Debt to Equity ratio (0.18) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.42 |
ROIC/WACC0.23
WACC9.79%
2.3 Liquidity
A Current Ratio of 5.44 indicates that BIO.B has no problem at all paying its short term obligations.
BIO.B has a Current ratio of 5.44. This is amongst the best in the industry. BIO.B outperforms 84.48% of its industry peers.
BIO.B has a Quick Ratio of 3.94. This indicates that BIO.B is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.94, BIO.B is doing good in the industry, outperforming 68.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
The earnings per share for BIO.B have decreased by -1.90% in the last year.
BIO.B shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.84% yearly.
The Revenue has decreased by -0.88% in the past year.
The Revenue has been growing slightly by 2.11% on average over the past years.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
The Earnings Per Share is expected to decrease by -2.66% on average over the next years.
The Revenue is expected to grow by 1.26% on average over the next years.
EPS Next Y-1.6%
EPS Next 2Y0.61%
EPS Next 3Y4.05%
EPS Next 5Y-2.66%
Revenue Next Year0.42%
Revenue Next 2Y1.43%
Revenue Next 3Y2.17%
Revenue Next 5Y1.26%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 30.14 indicates a quite expensive valuation of BIO.B.
BIO.B's Price/Earnings ratio is a bit cheaper when compared to the industry. BIO.B is cheaper than 70.69% of the companies in the same industry.
BIO.B's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.31.
With a Price/Forward Earnings ratio of 29.77, BIO.B can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, BIO.B is valued a bit cheaper than 68.97% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of BIO.B to the average of the S&P500 Index (36.59), we can say BIO.B is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.14 | ||
| Fwd PE | 29.77 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, BIO.B is valued cheaply inside the industry as 82.76% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.97 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.85
EPS Next 2Y0.61%
EPS Next 3Y4.05%
5. Dividend
5.1 Amount
No dividends for BIO.B!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:BIO.B (11/17/2025, 8:04:00 PM)
310.7
-3.7 (-1.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.73%
Inst Owner Change35.42%
Ins Owners3.84%
Ins Owner ChangeN/A
Market Cap8.41B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Analysts76
Price Target363.55 (17.01%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)-1.58%
PT rev (3m)-1.58%
EPS NQ rev (1m)0.4%
EPS NQ rev (3m)5.44%
EPS NY rev (1m)4.11%
EPS NY rev (3m)19.05%
Revenue NQ rev (1m)-0.11%
Revenue NQ rev (3m)3.42%
Revenue NY rev (1m)-0.23%
Revenue NY rev (3m)2.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.14 | ||
| Fwd PE | 29.77 | ||
| P/S | 3.29 | ||
| P/FCF | 24.97 | ||
| P/OCF | 17.11 | ||
| P/B | 1.25 | ||
| P/tB | 1.46 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.32%
EPS(NY)10.44
Fwd EY3.36%
FCF(TTM)12.44
FCFY4%
OCF(TTM)18.16
OCFY5.85%
SpS94.51
BVpS248.96
TBVpS213.22
PEG (NY)N/A
PEG (5Y)3.85
Graham Number240.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.42 |
F-Score5
WACC9.79%
ROIC/WACC0.23
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
EPS Next Y-1.6%
EPS Next 2Y0.61%
EPS Next 3Y4.05%
EPS Next 5Y-2.66%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
Revenue Next Year0.42%
Revenue Next 2Y1.43%
Revenue Next 3Y2.17%
Revenue Next 5Y1.26%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.54%
EBIT Next 3Y15.21%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES -CL B / BIO.B FAQ
What is the ChartMill fundamental rating of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.B.
What is the valuation status of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES -CL B (BIO.B). This can be considered as Overvalued.
How profitable is BIO-RAD LABORATORIES -CL B (BIO.B) stock?
BIO-RAD LABORATORIES -CL B (BIO.B) has a profitability rating of 4 / 10.
What are the PE and PB ratios of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
The Price/Earnings (PE) ratio for BIO-RAD LABORATORIES -CL B (BIO.B) is 30.14 and the Price/Book (PB) ratio is 1.25.
What is the earnings growth outlook for BIO-RAD LABORATORIES -CL B?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES -CL B (BIO.B) is expected to decline by -1.6% in the next year.